In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for 2024 by $3 billion at the time of its Q2 report. It now anticipates a ...
One of the current stars of the biotech world is Viking Therapeutics (NASDAQ: VKTX), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if ...